GlobeNewswire by notified

Corline Biomedical AB: Kardium rapporterar om första behandlade patient i klinisk studie i Tjeckien

Dela

Corline Biomedical AB (”Corline” eller ”bolaget”) meddelade tidigare att bolagets licenspartner Kardium har erhållit godkännande för kliniska försök med en CHS-coatad version av Globe-systemet i Kanada och Tjeckien. Nu rapporterar Kardium att det första patientfallet genomförts i Tjeckien med lyckat resultat.  

I studien i Tjeckien används CHS™-coatade katetrar för behandling av hjärtarytmier med en ny teknik, så kallad PFA (Pulsative Flow Ablation), som är en teknik där hjärtats signalsystem förändras genom att vävnad utsätts för hög elektriskt spänning istället för som tidigare värme eller kyla.

För mer information om studien och det rapporterade första patientfallet, se separat pressmeddelande på Kardiums hemsida, via https://kardium.com/kardium-news/

Vid frågor, vänligen kontakta
Henrik Nittmar, VD
Telefon: 018-71 30 90
E-post: henrik.nittmar@corline.se

Certified Adviser
Redeye AB, Mäster Samuelsgatan 42, 103 87 Stockholm. Telefon: +46 (0)8-121 576 90. E-post: certifiedadviser@redeye.se.



Corline Biomedical AB, noterat på First North Growth Market (CLBIO), arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget är i färd med att inleda fas 2-studier för Renaparin®, en kandidat för vilken Corline har erhållit särläkemedelsstatus (”Orphan Drug”) i Europa och USA och som är under utveckling för att förbättra utfallet av njurtransplantation. Dessutom genomförs prekliniska studier inom lungtransplantation för Renaparin®. Sedan tidigare ytbelägger bolaget medicintekniska produkter och har bland annat behandlat över 100 000 hjärtstentar som implanterats i patienter. Bolaget har nyligen tecknat avtal om samarbete med ett antal nya medicinteknikbolag. Läkemedelskandidaterna och de medicintekniska produkterna är baserade på samma grundteknologi.

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Number of Shares in eQ Plc has Increased through Subscription with Stock Options19.3.2024 07:30:00 CET | Press release

eQ Plc Total Number of Voting Rights and Capital 19 March 2024, at 8.30 a.m. A total number of 354,000 new shares in eQ Plc have been subscribed for with stock options of eQ Plc’s option scheme 2018. The entire subscription price of EUR 1,423,080 will be credited to the reserve for invested non-restricted equity. This means that eQ Plc's share capital remains unchanged. The total number of shares after the subscription is 41,224,698. The corresponding increase in the number of eQ Plc's shares has been entered into the Finnish trade register today on 19 March 2024, as of which date the new shares will establish shareholder rights. The shares will be traded on the Nasdaq Helsinki Ltd together with the old shares as of 20 March 2024. The terms and conditions of eQ Plc’s option scheme 2018 are available on Company's website at www.eQ.fi. Helsinki, 19 March 2024 eQ Plc Board of Directors Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733 Distribution: Nasdaq He

Mattermost offers Self-Hosted, Kubernetes-based Skype for Business Replacement Compatible with Microsoft Teams and GDPR/Schrems II for European Enterprises19.3.2024 07:00:00 CET | Press release

Mattermost’s self-sovereign collaboration platform helps European critical infrastructure organizations de-risk regulatory uncertainty from foreign-owned Software-as-a-Service infrastructure PARIS, March 19, 2024 (GLOBE NEWSWIRE) -- At the KubeCon Europe 2024 conference in Paris, France, Mattermost announced its self-hosted, Kubernetes-based replacement for Skype for Business designed for EU organizations requiring full data control to meet evolving GDPR and local regulatory requirements under Schrems II. As the 2025 Skype for Business end-of-life deadline nears, some EU critical infrastructure organizations are in urgent need of a compliant and effective collaboration platform to meet evolving EU data sovereignty requirements. Uncertainty in the future compatibility of U.S. and EU data control regulations for Software-as-a-Service infrastructure creates a material compliance risk for certain EU public sector and commercial enterprises managing sensitive data. “Mattermost delivers an a

ObsEva Announces Update on Board of Directors19.3.2024 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today. “We would like to warmly thank Catarina for her significant contribution to the company over the last years. We are grateful to have had the opportunity to work closely with her and we wish her continued success in her future endeavors,” said Ernest Loumaye, Board Chairman. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”.

AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning19.3.2024 07:00:00 CET | Press release

Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including partnerships, collaborations and non dilutive funding to drive the pipeline forward and create value for future funding rounds. His initial focus will be on the company’s candidate vaccine to treat chronic Hepatitis B and shape the future AstriVax vaccine pipeline. Leuven, Belgium, March 19, 2024 – AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer. Dr. Fanning further strengthens the company’s top-notch leadership team, joining CEO and co-founder Dr. Hanne Callewaert, CTO Dr. Wilfried Dalemans, CDO Dr. Mathieu Peeters, and CFO Barbara Freitag. Hanne Callewaert, Ph.D., co-founder and CEO of AstriVax, said: “Greg has been one of our scientific and strategic advisors almost from the very beginning and I am very happy to onboard him as part of our executive team. In

Brookfield Corporation Completes Annual Filings19.3.2024 01:55:08 CET | Press release

BROOKFIELD, NEWS, March 18, 2024 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has filed its 2023 annual materials on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2023, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available at www.brookfield.com and a hardcopy will be provided to shareholders free of charge upon request. About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have one of the largest pools of discretionary capital globally, which is deployed across our three core businesses – asset management, insurance solutions, and our operating businesses. Through our core businesses, we invest in real assets that form the backbone of the global economy to deliver

HiddenA line styled icon from Orion Icon Library.Eye